Investor Relations

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2022

Email Alerts

Sign up today and receive company updates straight to your inbox.

Latest Financial Results

Q2 2023

Quarter Ended Jun 30, 2023

Company Overview

Artelo Biosciences, Inc. is a clinical stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways including the endocannabinoid system. Artelo is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, pain, neuropathy, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the company applies leading edge scientific, regulatory, and commercial discipline to develop high-impact therapies.

Stock Snapshot

IR Contacts


Artelo Biosciences, Inc.
505 Lomas Santa Fe Drive
Suite 160
Solana Beach, CA 92075

Investor Relations

Crescendo Communications, LLC
T: 212-671-1020

Transfer Agent

American Stock Transfer & Trust Company, LLC
6201 15th Ave
Brooklyn, NY 11219
T: 800-937-5449, 8am-8pm Eastern, M-F